{"DataElement":{"publicId":"10694588","version":"1","preferredName":"Therapeutic Procedure Hemorrhagic Cystitis Administered Type","preferredDefinition":"A description of the therapy that was administered for hemorrhagic cystitis.","longName":"HEM_CYST_THRP_ADM_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"10694582","version":"1","preferredName":"Therapeutic Procedure Hemorrhagic Cystitis Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Inflammation of the bladder resulting in bloody urine._The act of having given something (e.g., a medication or test).","longName":"2512834v1.00:10694581v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"10694581","version":"1","preferredName":"Hemorrhagic Cystitis Administered","preferredDefinition":"Inflammation of the bladder resulting in bloody urine._The act of having given something (e.g., a medication or test).","longName":"C114666:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemorrhagic Cystitis","conceptCode":"C114666","definition":"Inflammation of the bladder resulting in bloody urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E456150D-55F5-18C1-E053-731AD00A93FB","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E456150D-55F6-18C1-E053-731AD00A93FB","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"10694583","version":"1","preferredName":"Hemorrhagic Cystitis Therapeutic Procedure Type","preferredDefinition":"Inflammation of the bladder resulting in bloody urine._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"THRPY_TP","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cidofovir","valueDescription":null,"ValueMeaning":{"publicId":"5632014","version":"1","preferredName":"Cidofovir","longName":"5632014","preferredDefinition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cidofovir","conceptCode":"C1600","definition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468C6C05-CDEA-0CF5-E053-F662850A61A4","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4562A8C-E9E1-1B26-E053-731AD00A7369","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"Hyperbaric oxygen","valueDescription":null,"ValueMeaning":{"publicId":"2576545","version":"1","preferredName":"Whole body hyperbaric oxygen therapy","longName":"2576545","preferredDefinition":"Oxygen that is at an atmospheric pressure higher than the pressure at sea level.  Breathing hyperbaric oxygen to enhance the effectiveness of radiation therapy is being studied.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperbaric Oxygen","conceptCode":"C2351","definition":"Oxygen that is administered at a higher pressure compared to standard (i.e. sea-level) atmospheric pressure.  Administration of oxygen under hyperbaric conditions enhances the delivery of oxygen to hypoxic tumor cells, thereby increasing their sensitivity to radiation and chemotherapy.  In addition, hyperbaric oxygen may improve the healing of radiation-induced injuries by improving oxygen delivery to damaged tissue. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F80E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-12","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4562A8C-E9E2-1B26-E053-731AD00A7369","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"BK-virus Cytotoxic T-lymphocyte therapy","valueDescription":null,"ValueMeaning":{"publicId":"10694584","version":"1","preferredName":"BK Virus Cytotoxic T-Lymphocyte","longName":"10694584v1.00","preferredDefinition":"A double stranded DNA virus in the polyomavirus family. It is widespread but usually causes an asymptomatic infection, except in immunocompromised individuals._Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BK Virus","conceptCode":"C89820","definition":"A double stranded DNA virus in the polyomavirus family. It is widespread but usually causes an asymptomatic infection, except in immunocompromised individuals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytotoxic T-Lymphocyte","conceptCode":"C12543","definition":"Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4562A8C-E9DE-1B26-E053-731AD00A7369","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4562A8C-E9E3-1B26-E053-731AD00A7369","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"Adenovirus Cytotoxic T-lymphocyte therapy","valueDescription":null,"ValueMeaning":{"publicId":"10694585","version":"1","preferredName":"Adenoviridae Cytotoxic T-Lymphocyte","longName":"10694585v1.00","preferredDefinition":"A group of DNA containing viruses which infect mammals and are capable of causing respiratory disease, including one form of the common cold._Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviridae","conceptCode":"C14179","definition":"A group of DNA containing viruses which infect mammals and are capable of causing respiratory disease, including one form of the common cold.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytotoxic T-Lymphocyte","conceptCode":"C12543","definition":"Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4562A8C-E9DF-1B26-E053-731AD00A7369","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4562A8C-E9E4-1B26-E053-731AD00A7369","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"Bladder irrigation","valueDescription":null,"ValueMeaning":{"publicId":"10694586","version":"1","preferredName":"Bladder Irrigation","longName":"10694586v1.00","preferredDefinition":"Instillation of a solution into the bladder to provide cleansing or medication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Irrigation","conceptCode":"C15397","definition":"Instillation of a solution into the bladder to provide cleansing or medication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4562A8C-E9E0-1B26-E053-731AD00A7369","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4562A8C-E9E5-1B26-E053-731AD00A7369","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4562A8C-E9E6-1B26-E053-731AD00A7369","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"10694587","version":"1","preferredName":"Hemorrhagic Cystitis Therapeutic Procedure Type","preferredDefinition":"Inflammation of the bladder resulting in bloody urine._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"10694587v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemorrhagic Cystitis","conceptCode":"C114666","definition":"Inflammation of the bladder resulting in bloody urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4564A31-916A-1E5B-E053-731AD00A096F","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4561D1A-22AF-1984-E053-731AD00AEBDE","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What therapy was administered for hemorrhagic cystitis?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Therapy/s administered to patient for hemorrhagic cystitis during this reporting period:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E456594C-02A1-1FE1-E053-731AD00A52ED","latestVersionIndicator":"Yes","beginDate":"2022-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-21","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}